Key terms
About ACIU
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ACIU news
Mar 19
1:50am ET
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)
Mar 14
4:45pm ET
AC Immune files $350M mixed securities shelf
Mar 11
1:00am ET
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Elevation Oncology (ELEV) and AC Immune SA (ACIU)
Feb 01
6:28am ET
Buy Rating Affirmed for AC Immune SA Amid Promising Immunotherapy Program Developments
Jan 22
7:09am ET
AC Immune to regain global rights to crenezumab, semorinemab
Jan 03
8:20am ET
AC Immune provides update on program progress, says key milestones in 2024
No recent news articles are available for ACIU
No recent press releases are available for ACIU
ACIU Financials
Key terms
Ad Feedback
ACIU Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ACIU Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range